Skip to content
Screener

BridgeBio Pharma BBIO Pre-Tax Income

Pre-Tax Income at other companies

Pfizer logo
PfizerPFE
-$653M-121%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$113.38M-192%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$61.38M-79.4%
ALN
Alnylam PharmaceuticalsALNY
$177.81M+603%
Celcuity logo
CelcuityCELC
-$52.84M-42.8%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$644.37M-160%

Segments

By segment

See full
Reportable Segment-$155.89M

Other financials

Income statement

See full
Revenue$243.7M+120%
Gross profit$228.6M+114%
Operating income-$107.1M+20.3%
Net income-$155.9M+15.2%
EPS (diluted)-$0.78+17.9%

Balance sheet

See full
Cash & equivalents$680.0M-9.5%
Total debt$3.3B+36,912%
Total equity-$2.5B-40.7%
Total assets$1.2B+12.7%

Cash flow

See full
Operating cash flow-$71.1M+11.9%
CapEx$443.0K-25.4%
Free cash flow-$71.5M+12.0%

Valuation

See full
Market cap$16.55B+79.4%
Enterprise value$19.13B+126%
P/S23.2×-15.9×

Profitability

See full
Gross margin94.4%-1.8pp
Operating margin-69.8%-29.9pp
Net margin-98.5%-40.7pp
FCF margin-61.1%-26.8pp

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio1.2×-4.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:31 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001743881-26-000027
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net loss from equity method investments(6,435)(20,189)(24,718)(35,745)
Other income, net5,5876,5489,84014,779
Total other expense, net(48,812)(47,380)(109,411)(112,616)
Loss before income taxes(155,891)(181,658)(322,446)(351,266)
Provision for income taxes2,1002,100
Net loss(155,891)(183,758)(322,446)(353,366)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests3,6751,8556,1874,041
Net loss attributable to common stockholders of BridgeBio$(152,216)$(181,903)$(316,259)$(349,325)

Item 1. Financial Statements (Unaudited)

FAQ

What is BridgeBio Pharma's pre-tax income?
BridgeBio Pharma (BBIO) reported pre-tax income of -$155.89M in Q2 2026.
How has BridgeBio Pharma's pre-tax income changed year-over-year?
BridgeBio Pharma's pre-tax income increased by 14.2% year-over-year, from -$181.66M to -$155.89M.
What is the long-term trend for BridgeBio Pharma's pre-tax income?
Over 3 years (2022 to 2025), BridgeBio Pharma's pre-tax income has grown at a 14.8% compound annual growth rate (CAGR), from -$484.65M to -$732.5M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about BridgeBio Pharma's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude